Compare Heron Therapeutics Inc (HRTX) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while ProShares UltraPro Short QQQ ETF trades at $33.01 (market cap $2.23B). The key difference: ProShares UltraPro Short QQQ ETF is far larger — about 32.8× Heron Therapeutics Inc's market cap, and ProShares UltraPro Short QQQ ETF is more actively traded (60,436,012 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| HRTX | SQQQ | |
|---|---|---|
Market Cap | $68.01M | $2.23B |
Volume | 1,891,941 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.49 | $89.43 |
52-Week Low | $0.27 | $31.83 |
Typical Hold Time | 35 Days | 12 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
SQQQ (ProShares UltraPro Short QQQ) trades at $33.20, up 3.49% today, reflecting bearish market sentiment toward the Nasdaq 100. Technical indicators show a predominantly bearish signal with moving averages heavily weighted toward selling pressure. The ETF is designed to deliver triple the inverse daily performance of the Nasdaq 100, making it a tactical tool for hedging or speculating on tech sector declines.
SQQQ's outlook remains tied to Nasdaq 100 volatility, with potential gains during market downturns but significant decay risk in flat or rising markets. Investors should consider the high-risk, leveraged nature of this instrument and its suitability primarily for short-term hedging strategies rather than long-term holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
